Concepedia

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R Brown, Bertrand Coiffier, Julio Delgado, Miklós Egyed, Paolo Ghia, Árpád Illés, Wojciech Jurczak, Paula Marlton,

The Lancet Oncology · 2017 · 247 citations · 14 references

DOIFull text

Open access

Concepts

References

14

Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

Hartmut Döhner, Stephan Stilgenbauer, Axel Benner et al. · New England Journal of Medicine · 2000 · 3.3K citations

, , +17

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text

, , +14

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

, , +14

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

, , +17

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

, , +11